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Available online 23 June 2016Objectives: To describe the incidence, onset, predictors and outcome of ventricular tachyarrhythmia (VTA) in
pregnant women with heart disease.
Background: VTA during pregnancy will cause maternal morbidity and even mortality and will have impact on
fetal outcome. Insufﬁcient data exist on the incidence and outcome of VTA in pregnancy.
Methods and results: From January 2007 up to October 2013, 99 hospitals in 39 countries enrolled 2966 pregnan-
cies in women with structural heart disease. Forty-two women (1.4%) developed clinically relevant VTA during
pregnancy,which occurredmainly in the third trimester (48%). NYHA class N1 before pregnancywas an indepen-
dent predictor for VTA. Heart failure during pregnancy was more common in women with VTA than in women
without VTA (24% vs. 12%, p = 0.03) and maternal mortality was respectively 2.4% and 0.3% (p = 0.15). More
women with VTA delivered by Cesarean section than women without VTA (68% vs. 47%, p = 0.01). Neonatal
death, preterm birth (b37 weeks), low birthweight (b2500 g) and Apgar score b7 occurred more often in
women with VTA (4.8% vs. 0.3%, p = 0.01; 36% vs. 16%, p = 0.001; 33% vs. 15%, p = 0.001 and 25% vs. 7.3%,
p = 0.001, respectively).
Conclusions: VTA occurred in 1.4% of pregnant womenwith cardiovascular disease, mainly in the third trimester,
andwas associatedwith heart failure during pregnancy. NYHA class before pregnancywas predictive. VTAduring
pregnancy had clear impact on fetal outcome.
© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.04.0/).Keywords:
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Heart disease is an important cause of maternal death and, surpris-
ingly, rates are increasing [1,2]. Interim analysis of the Registry Of
Pregnancy and Cardiac disease (ROPAC) reported a 100 times higher
maternal mortality rate in women with heart disease compared to the
general pregnant population [3]. This raises serious safety concerns for
womenwith structural heart disease andmakes it imperative to identi-
fy those at greatest risk of complications during pregnancy.e under the CC BY license (http://creativecommons.org/licenses/by/4.04.0/).
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rare during normal pregnancy (2 per 100,000 pregnancies) [4,5], but
may be associated with maternal hemodynamic compromise causing
adverse consequences for both mother and fetus [6]. This data, particu-
larly in women with structural heart disease, however is scarce and is
generally poorly reported in the literature. The incidence of VTA in preg-
nant women with heart disease has been documented ranging from
1.0% to 1.4% [1,7]. In patients with congenital heart disease, VTA occurs
in up to 1.6% [1,8], whereas there are hardly any reports on the inci-
dence of VTA in pregnant women with valvular heart disease, ischemic
heart disease or cardiomyopathy. Also, insufﬁcient data exist on the out-
come of VTA during pregnancy. Previous studies mostly report on ar-
rhythmias in general, but it is of major importance to distinguish
potentially life-threatening VTA from the mostly benign supraventricu-
lar tachycardia. This study describes the incidence, onset, predictors and
outcome of VTA during pregnancy in women with structural heart
disease.
2. Methods
2.1. Study design
The Registry Of Pregnancy And Cardiac disease (ROPAC) is part of
the EURObservational Research Programme (EORP of the European
Society of Cardiology) and was initiated in 2007. From January 2008
pregnant women with heart disease were included prospectively.
Patients from 2007 were included retrospectively, assuming that the
complete data were available and reliable. All patients included up to
October 2013were included in the current interim analysis. In this peri-
od, 99 hospitals in 39 countries contributed to the registry and a total of
2966 pregnant women with congenital heart disease (CHD), valvular
heart disease (VHD), cardiomyopathy (CMP), ischemic heart disease
(IHD), aortic pathology (AOP) or pulmonary hypertension were en-
rolled. Non-structural heart disease, for example arrhythmia occurring
in the context of a structurally normal heart, was excluded. The study
protocol and ﬁrst results of this registry were published in 2013 [3]. In-
formed consent was obtained from the patients and the study protocolTable 1
Baseline characteristics of cardiac patients with and without VTAa.
Total group
(n = 2966)
P
(
Mean age in years (SDb) 29.3 (5.6) 2
Nulliparity (%) 45 5
Clinical signs of heart failure (%) 10 2
Hypertension (%) 6.5 4
Current smoker (%) 4.3 5
Developing countries (%) 35 4
NYHA classc
NYHA class 1 (%) 73 5
NYHA class 2 (%) 22 3
NYHA class 3 (%) 2.9 1
NYHA class 4 (%) 0.3 0
Type of heart disease
Congenital heart disease (%) 56 4
Valvular heart disease (%) 32 1
Ischemic heart disease (%) 1.6 2
Cardiomyopathy (%) 7 2
Aortic pathology (%) 3.4 7
Pulmonary arterial hypertension (%) 0.4 0
Medication use before pregnancy
Beta-blocker (%) 12 1
Other anti-arrhythmic drugs (%) 3.1 0
Diuretics (%) 5.8 9
ACE inhibitors (%)d 3.9 4
Calcium antagonists (%) 0.2 0
a VTA: ventricular tachyarrhythmia.
b SD = STANDARD deviation.
c NYHA class = New York Heart Association functional class.
d ACE inhibitors: Angiotensin-converting enzyme inhibitors.conforms to the ethical guidelines of the 1975 Declaration of Helsinki as
reﬂected in a priori approval by the institution's human research
committee.
2.2. Data
VTA has been deﬁned as three ormore consecutive ventricular beats
with a mean rate of more than 100 beats per minute; however, only
clinically relevant VTA (when the patient had physical complaints,
needed treatment for VTA or when the patient had more than 100 con-
secutive beats) was included. Onset of VTA, given in weeks of gestation,
was calculated using the expected date of delivery. Data up to oneweek
after delivery was available for all patients. Baseline characteristics be-
fore pregnancy were analyzed, including cardiac diagnosis, maternal
age, parity, clinical signs of heart failure, hypertension, smoking status,
medication use and New York Heart Association (NYHA) functional
class. The following cardiac diagnoses were included: CHD, VHD, IHD,
CMP, AOP and pulmonary hypertension. The type of cardiac lesions
were divided into three categories for the univariable logistic regression
analysis: right sided lesions (e.g. Ebstein anomaly, tetralogy of Fallot,
pulmonary stenosis), left sided lesions (e.g. aortic valve disease, mitral
valve disease and most cardiomyopathies) and shunt lesions (e.g. atrial
septal defects and ventricular septal defects). Participating countries
were classiﬁed as developedor developing according to the Internation-
al Monetary Fund classiﬁcation [9].
2.3. Statistical methods
Categorical data are presented as frequencies (numbers) and per-
centages. Normality of continuous data was checked by one-sample
Kolmogorov–Smirnov tests and histograms. Continuous data are pre-
sented as mean values ± one standard deviation (SD) when normally
distributed. The chi-squared test was used to compare differences in
categorical data between independent patient groups. Fisher's exact
tests were applied if any expected cell count was less than 5. The
Student's t-test was used to compare differences in continuous data be-
tween independent patient groups.Mean birthweightwas corrected foratients with VTA
n = 42)
Patients without VTA
(n = 2924) p-Value
8.9 (5.7) 29.3 (5.6) 0.78
5 45 0.21
1 10 0.02
.9 6.5 1.00
.1 4.3 0.68
5 35 0.17
0.002
0 73
8 22
1.9 2.8
0.3
8 56 0.28
4 32 0.01
.4 1.6 0.68
9 7 b0.001
.1 3.4 0.18
0.4 1.00
7 12 0.39
3.1 0.64
.5 5.7 0.30
.8 3.9 0.68
0.2 0.34
Fig. 1. Diagnoses per cardiac disease category. CHD = congenital heart disease, VHD = valvular heart disease, CMP = cardiomyopathy, AOP = aortic pathology.
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sion. The birthweight was not normally distributed; therefore both the
median birthweight and the corrected mean birthweight are shown in
this article. Baseline patient characteristics associated with VTA were
identiﬁed with univariable logistic regression analysis. Available echo-
cardiographic data (moderate or severely impaired systemic ventricular
function) were also analyzed in the univariable logistic regression anal-
ysis. The multivariable analysis consists of variables that were associat-
ed with an increased incidence of the studied endpoint (p b 0.15).
For each 10 cases/patients, one of the most signiﬁcant univariable
predictors was included in the multivariable analysis. A p-value b0.05
(2-sided test) was considered statistically signiﬁcant. All statistical
analyses were performed using SPSS 21.0 (SPSS Inc., Chicago).3. Results
3.1. Baseline characteristics
Of the 2966 patients included in the registry, 42 (1.4%) patients de-
veloped clinically relevant VTA during pregnancy. One patient had ven-
tricular ﬁbrillation (VF), the other patients had ventricular tachycardia.
Baseline characteristics of pregnant patients with and without VTA are
shown in Table 1. The incidence of VTA was 1.2% in CHD patients, 0.6%
in VHD patients, 5.9% in CMP patients, 2.1% in IHD patients and 3.0% in
AOP patients. VTAwas not observed in patients with pulmonary hyper-
tension. The diagnoses per cardiac disease category are shown in Fig. 1.
Before pregnancy, three patients had pacemaker-dependent rhythm. All
others were in sinus rhythm.Fig. 2. The occurrence (onset) of VTA during pregnancy in women with heart disease.
VTA = ventricular tachyarrhythmia.3.2. Onset of VTA
Fig. 2 shows that VTA mainly occurred in the third trimester (48%).
Fig. 3 shows the onset of VTA per cardiac disease category.3.3. Predictors
The results of the univariable and multivariable logistic regression
are shown in Table 2.
3.4. Medication before and during pregnancy
Of the 42 patients with VTA, 31% used cardiac medication before
pregnancy. The medication used before pregnancy is shown in Table 1.
During pregnancy, 74% of the VTA patients used medication: 57% used
beta-blockers, 12% used other anti-arrhythmic drugs and 12% used di-
uretics. Amiodarone was used in 3 of the 42 patients with VTA.
3.5. Maternal outcome
Pregnancy outcome until one week after delivery is presented in
Table 3. Heart failurewas diagnosed in 10 VTA patients (24%), occurring
Fig. 3. The occurrence of VTA during pregnancy per cardiac disease category. The number
of patients per category is shown between brackets. CHD = congenital heart disease,
VHD = valvular heart disease, CMP = cardiomyopathy, AOP = aortic pathology, All
cardiac = CHD + VHD + CMP + AOP. *The time of onset of VTA was missing in four
CHD patients.
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and in the remaining three patients the temporal relationship was
unclear. Maternal death occurred in one patient (2.4%). This was a
36-year-old woman with pulmonary atresia, who had a bioprosthetic
pulmonary valve replacement before pregnancy. She was taking beta-
blockers because of aortic dilatation and used LMWH throughout
pregnancy. At 17weeks of pregnancy, she had an out of hospital cardiac
arrest due to VF. She survived resuscitation, but was left in a persistent
vegetative state. She was ventilated until delivery at 32 weeks and died
one week postpartum.
3.6. Delivery and fetal outcome
Fetal outcome is shown in Table 3.Mode of delivery in patients with
VTA was by emergency Cesarean section in 20%, elective Cesarean sec-
tion in 48% and vaginally in 32%. No fetal death occurred in VTA patients
(Table 3), but there were two neonatal deaths. A 28-year-old patient
with non-obstructive CMP developed VTA in week 6 of pregnancy.
She underwent Cesarean section at 29 weeks for cardiac reasons,
followed by an unexplained neonatal death. The second neonatal
death was due to acute respiratory distress syndrome (ARDS) oneTable 2
Pre-pregnancy predictors for VTA.
Univariable
Odds
ratio 95% CI p-Value
Congenital heart disease 0.72 (0.39–1.32) 0.28
Valvular heart disease 0.35 (0.15–0.84) 0.02
Cardiomyopathy 5.76 (2.90–11.40) b0.001
Right sided lesion 0.72 (0.32–1.62) 0.43
Left sided lesion 1.71 (0.91–3.20) 0.09
Shunt lesion 0.61 (0.26–1.46) 0.27
NYHA class N 1 2.98 (1.62–5.49) b0.001
Nulliparity 1.48 (0.80–2.72) 0.21
Hypertension 0.74 (0.18–3.08) 0.68
Clinical signs of pre-pregnancy heart failure 2.59 (1.23–5.47) 0.01
Developing countries 1.53 (0.83–2.82) 0.17
Any medication use before pregnancy 1.16 (0.60–2.24) 0.66
Beta-blocker use before pregnancy 1.43 (0.63–3.24) 0.39
Echo prior to pregnancy
Systemic ventricular dysfunction
moderate/severely impaired
4.59 (1.92–10.96) 0.001
Multivariable
Cardiomyopathy 2.70 (0.95–7.69) 0.06
NYHA class N 1 2.64 (1.12–6.20) 0.03
Clinical signs of pre-pregnancy heart failure 0.88 (0.29–2.64) 0.82
Systemic ventricular dysfunction 2.25 (0.78–6.48) 0.13week postpartum. The mother of this child had subaortic stenosis and
a history of heart failure before pregnancy.
4. Discussion
This is the ﬁrst detailed study of pregnancy outcome after VTA in pa-
tients with cardiovascular disease. In this large prospective internation-
al registry of 2966 pregnancies with heart disease, the incidence of VTA
during pregnancy was 1.4% and occurred mainly in the third trimester.
NYHA class N1 before pregnancy was an independent predictor of
VTA. VTA was associated with a marked increase in the neonatal death
rate, preterm birth rate, low birthweight rate and poor Apgar score.
4.1. Incidence of VTA
Existing data on the incidence of VTA during pregnancy in patients
with heart disease is scarce. Siu et al. studied pregnancy outcome in
two cohorts of women with heart disease. VTA occurred in 4 cases
in the cohort of 276 pregnancies and in 6 patients in the cohort of
599 pregnancies [1,7]. The incidence of VTA in our study (1.4%) was
comparable to the incidence of Siu et al.'s retrospective (1.4%) and pro-
spective (1.0%) studies.
4.1.1. Congenital heart disease
VTAduring pregnancy inwomenwith CHD is rare.We observed VTA
in 1.2% of CHD patients, in keeping with the reported incidence range
from 0.4 to 1.6% [1,8]. Patients with repaired CHD in the study of Niwa
et al. [10] had a signiﬁcantly higher incidence of VTA than healthy preg-
nant women. In their study, the prevalence of non-sustained VTA was
14% with the highest incidence in patients with previous surgical cor-
rection of Tetralogy of Fallot (TOF) [8,10,11]. In our study, VTA occurred
in 2.5% of TOF patients (3 out of 119 patients), however, we only includ-
ed patients with symptomatic VTA.
4.1.2. Cardiomyopathy
VTA occurred remarkably often in patients with CMP (7.4%) in our
study. In the study of Grewal et al. [12], VTA occurred in 3% of dilated
CMP patients. In patients with hypertrophic CMP, the incidence of
arrhythmias (including VTA) was not increased during pregnancy
[13]. However, in hypertrophic CMP patients with an Implantable
Cardioverter Deﬁbrillator (ICD), VTA is a common complication with
an observed incidence of 22% during pregnancy [14]. Some case reports
of VTA in patients with peripartum cardiomyopathy (PPCM) have been
published previously [15–17]. In our study VTA did not occur in the
33 PPCM patients.
4.1.3. Valvular heart disease
We found that 0.7% of the patients with VHD developed VTA during
pregnancy and the majority had mitral valve disease. In the literature,
ventricular arrhythmia, not further deﬁned, has been described in 1.5%
of pregnant women with VHD [18] and occurred in 1.2% in Siu et al.'s
prospective study.
4.1.4. Ischemic heart disease
Although seldom encountered during pregnancy, IHD is amajor and
increasing cause of maternal death [19]. In the existing literature, cases
of VF, but not ventricular tachycardia, have been reported during preg-
nancy in patients with a myocardial infarction [20,21]. In our registry,
VTA occurred in only one patient with IHD (2.1%).
4.2. Predictors for VTA
Womenwith a limited exercise tolerance are at higher risk of devel-
oping complications during pregnancy [4], and consequently, we were
not surprised to ﬁnd that NYHA class N1 before pregnancy is an inde-
pendent predictor of VTA. Any disease process that affects the
Table 3
Pregnancy outcome in cardiac patients with and without VTA
Outcome until one week after pregnancy.
Total group
(n = 2966)
Patients with VTA
(n = 42)
Patients without VTA
(n = 2924) p-Value
Maternal mortality (%) 0.4 2.4 0.3 0.15
Cardiac
Heart failure (%) 13 24 12 0.03
Thromboembolic events (%) 0.8 0 0.8 1.00
Endocarditis (%) 0.2 0 0.2 1.00
Bleeding during pregnancy (%) 6.2 4.8 6.2 1.00
Obstetric
Intra-uterine growth retardation (%) 4.6 4.8 4.6 0.72
Pregnancy induced hypertension (%) 2.3 0 2.4 0.63
(Pre)eclampsia (%) 2.4 0 2.5 0.63
Cesarean section (%) 48 68 47 0.01
Fetal outcome
Miscarriage (b24 weeks; %) 2.7 0 2.7 0.26
Late fetal death (≥24 weeks; %) 0.7 0 0.7 1.00
Neonatal death (%) 0.3 4.8 0.3 0.01
Median pregnancy duration (weeks) 38.2 37.4 39.0 b0.001
Apgar score b 7 (%) 7.6 25 7.3 0.001
Preterm birth (b37 weeks; %) 16 36 16 0.001
Low birthweight (b2500 g; %) 15 33 15 0.001
Median birthweight (g) – 2730 3020 0.006
Corrected mean birthweight (g)a – 3283 3289 0.94
a Birthweight corrected for: gestational age, fetal sex, maternal age, and diabetes.
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may disrupt the electrical integrity of the myocardium and induce
VTA [11]. CMP in general is known to be associated with ventricular ar-
rhythmias as it is often associated with diminished ventricular function
[22]. In accordance with this, we found that a diagnosis of CMP showed
a borderline signiﬁcance (0.06) in the multivariable analysis.4.3. Onset during pregnancy
Nakagawa et al. [23] studied 11pregnantwomenwho experienced a
new onset of ventricular tachycardia during pregnancy. In their study,
the onset of ventricular tachycardia was distributed equally over the
three trimesters and did not occur in the postpartum period. Overall,
VTA occurred throughout pregnancy but more in the third trimester in
our study, with CHD patients experiencing VTA more in the second
and third trimester, while CMP patients typically present with VTA at
the end of pregnancy (≥32 weeks), perhaps reﬂecting a different
threshold for VTA. These ﬁndings raise a number of hypotheses regard-
ing the mechanism of VTA during pregnancy. Cardiac output, induced
by a decline in systemic vascular resistance, rises rapidly through the
ﬁrst and second trimesters reaching a peak at around 26 weeks and re-
maining at this level until the endof pregnancy [24]. The increase in car-
diac output is due to an increase in heart rate and stroke volume. The
greater ﬁlling, resulting in an increase in cardiac end diastolic volumes,
will result in myocardial stretch which has been shown to induce VTA
[25]. In addition to these physiological changes during normal pregnan-
cy, womenwith structural heart disease have limited ability to adjust to
the hemodynamic requirement of pregnancy, and this may become
manifest as systolic and diastolic cardiac dysfunction during pregnancy
[24], which again may increase the risk of VTA. Finally, the increased
sympathetic activity observed during pregnancy has also been sug-
gested to be responsible for the increased incidence of arrhythmias
and it is well known that high plasma catecholamine concentrations
and adrenergic receptor sensitivity may trigger VTA [26]. In all patients,
the hemodynamic overload may well have contributed to the develop-
ment of VTA, while the increased sympathetic activity may bemore im-
portant in speciﬁc groups such as cardiomyopathy patients, which may
be more susceptible.4.4. Maternal outcome
VTA, outside of pregnancy, is associated with sudden cardiac death,
especially in the presence of cardiomyopathy [22,27]. Previous publica-
tions on VTA during pregnancy were either case reports or studies
which have only reported on its incidence. Therefore, it is not well
known whether VTA during pregnancy carries an extra high risk for
mortality.We did not detect a signiﬁcant increase inmaternalmortality,
but it must be noted that, although our series is by far the largest, our
mortality numbers are still small and we have analyzed outcome only
until one week after pregnancy. The timing of heart failure and VTA
seemed to be associated in our study. However, a clear cut pattern
was not found as some patients developed heart failure shortly after
VTA, while others developed heart failure prior to VTA.
4.5. Delivery and fetal outcome
Women with VTA during pregnancy had higher rates of neonatal
death, preterm birth and poor Apgar score. Certainly, low birthweight
was more common in patients with VTA than in patients without VTA
and the median birthweight was signiﬁcantly lower in VTA patients.
However, the corrected mean birthweight did not signiﬁcantly differ
between the two groups, suggesting that the difference in birthweight
is primarily due to the higher preterm birth rate. Physicians often opt
for preterm delivery in women with VTA, partly to shorten the period
of hemodynamic compromise and also to be able to institute amore ag-
gressive therapy for VTA, which might have an adverse effect on the
fetus. Equally, the decision for early delivery may have a negative im-
pact on neonatal development [28].
4.6. Management of VTA during pregnancy
In general, the management of VTA in pregnancy is similar to that
outside of pregnancy. For VTA with hemodynamic compromise, imme-
diate cardioversion, which is reported to be safe in all phases of preg-
nancy, is recommended [4]. When the patient is not hemodynamically
compromised, medication should be considered. The concerns with
anti-arrhythmic drug use during pregnancy relate to their effects on
fetal growth and development. Beta-blockers are the drug of choice
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ingpregnancy is generallywell tolerated by bothmother and fetus, even
though it has been associated with a decrease in fetal heart rate, low
blood glucose and reduced birthweight [22,29]. In our study, most pa-
tients with VTA (57%) were treated with a beta-blocker, other antiar-
rhythmic drugs were prescribed in 12% of the patients. Amiodarone
was used in 3 of the 42 patients with VTA in our study and may have
had a deleterious effect on one fetus, perhaps causing growth retarda-
tion requiring earlier delivery [22]. A multidisciplinary approach with
close monitoring of mother and baby with timely intervention for
both is required to optimize maternal and fetal outcomes.
4.7. Implications on clinical practice
The signiﬁcance of VTA during pregnancy in women with heart dis-
ease lies in the fact that it carries a higher preterm birth rate and, conse-
quently, lower birthweight and poor Apgar score. Cardiac patients in
NYHA class N1 and patients with CMP are at particular risk and should
be counseled about the risks before pregnancy and followed closely dur-
ing pregnancy.
4.8. Study limitations
This dataset, like in other registry collected datapoints, was limited
by the availability of information on the past history. In our registry
missing data concerning the current pregnancy ranged from 0% to 4%
for all parameters except two: smoking (14%) and left ventricular dys-
function (36%). Although VTA is an important complication especially
in women with underlying heart disease, its incidence is low, reﬂected
in the number of cases. This makes it difﬁcult to draw any ﬁrm conclu-
sions. The severity of the VTAs was not reported in detail.
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